Regulators in the US and Europe have agreed to review AbbVie’s venetoclax as a potential treatment for certain adults with chronic lymphocytic leukaemia (CLL).

The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) and granted priority review for venetoclax to treat CLL in adults who have received at least one prior therapy, including patients with 17p deletion.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition, the European Medicines Agency (EMA) has validated the company’s marketing authorisation application (MAA) for venetoclax to treat CLL patients with 17p deletion or TP53 mutation.

Venetoclax is an investigational oral B-cell lymphoma-2 (BCL-2) inhibitor being evaluated to treat several types of cancer.

"Patients are always our number one priority and we accelerated our efforts to bring venetoclax, the first BCL-2 inhibitor, to patients in need of new therapies."

The drug is designed to selectively inhibit the function of the BCL-2 protein, which prevents programmed cell death of some cells, including lymphocytes, and can be over expressed in some cancer types.

See Also:

The company has collaborated with Genentech and Roche to develop venetoclax, which is currently being evaluated in phase III clinical trials to treat relapsed / refractory CLL, along with trials in various other cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AbbVie research and development executive vice-president and chief scientific officer Michael Severino said: "The FDA acceptance and EMA validation of AbbVie’s Venetoclax submissions mark a major step forward as we work to become a global leader in oncology, providing new therapies for patients with cancer.

"Patients are always our number one priority and we accelerated our efforts to bring venetoclax, the first BCL-2 inhibitor, to patients with CLL in need of new therapies, including those with 17p deletion who typically have a poor prognosis."

Both NDA and MAA were supported by data from a Phase II data study, which met its primary endpoint of achieving an overall response rate, with no unexpected safety signals.

The company noted that venetoclax is an investigational compound and its safety and efficacy have not been evaluated by the FDA or any other health authority.